Phaseline

Companies › Eledon Pharmaceuticals

Eledon Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Genitourinary, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tegoprubart (AT-1501)
CD40 ligand inhibitor
CD40LGPhase 1Prevention of Rejection in Kidney Transplant; Type 1 Diabetes Mellitus; Diabete Type 1Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05027906Tegoprubart (AT-1501)Phase 1Prevention of Rejection in Kidney TransplantGenitourinaryJan 2027
NCT06305286Tegoprubart (AT-1501)Phase 1Type 1 Diabetes MellitusMetabolic and endocrineMar 2029
NCT07592000Tegoprubart (AT-1501)Phase 1Diabete Type 1GenitourinaryJan 2030

From the company's SEC filings

Cash and short-term investments of $89m on 2026-06-30; operating cash outflow about $92m a year; runway about 12 months at that burn, to Jun 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD40LG (1)

Companies with the same targets

UCB Biopharma SRL AbbVie Amgen

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.